Jefferies stays Buy on Nektar Therapeutics (NKTR) after Rezpeg data hits upside estimates, sees 10-30% stock move into Ph3

April 20, 2026 9:48 AM

Jefferies analyst Roger Song reiterated a Buy rating ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

StreetInsider